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Abstract
Although CD133 has been reported to be a promising colon cancer stem cell marker, the biological functions of CD133
+
colon cancer cells remain controversial. In the present study, we investigated the biological differences between CD133
+
and CD133
2 colon cancer cells, with a particular focus on their interactions with cancer-associated fibroblasts, especially
CD10
+ fibroblasts. We used 19 primary colon cancer tissues, 30 primary cultures of fibroblasts derived from colon cancer
tissues and 6 colon cancer cell lines. We isolated CD133
+ and CD133
2 subpopulations from the colon cancer tissues and
cultured cells. In vitro analyses revealed that the two populations showed similar biological behaviors in their proliferation
and chemosensitivity. In vivo analyses revealed that CD133
+ cells showed significantly greater tumor growth than CD133
2
cells (P=0.007). Moreover, in cocultures with primary fibroblasts derived from colon cancer tissues, CD133
+ cells exhibited
significantly more invasive behaviors than CD133
2 cells (P,0.001), especially in cocultures with CD10
+ fibroblasts
(P,0.0001). Further in vivo analyses revealed that CD10
+ fibroblasts enhanced the tumor growth of CD133
+ cells
significantly more than CD10
2 fibroblasts (P,0.05). These data demonstrate that the in vitro invasive properties and in vivo
tumor growth of CD133
+ colon cancer cells are enhanced in the presence of specific cancer-associated fibroblasts, CD10
+
fibroblasts, suggesting that the interactions between these specific cell populations have important roles in cancer
progression. Therefore, these specific interactions may be promising targets for new colon cancer therapies.
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Introduction
Colorectal cancer is the second leading cause of cancer-related
death in the Western world and its incidence is increasing in Asian
countries as a result of changes toward a westernized diet [1].
Recently, the concept of cancer stem cells (CSCs) has been focused
upon in the biology of colorectal cancer. Colon cancer shows a
marked degree of morphological and functional heterogeneity in
its cells. Among these cell populations, CSCs in particular have
been reported to possess tumorigenic and treatment-resistant
activities [2]. Therefore, the isolation and characterization of colon
CSCs may help toward the development of novel diagnostic and
therapeutic procedures [3].
Human prominin-1 (PROM1, CD133) is a 5-transmembrane
glycoprotein of 865 amino acids with a total molecular weight of
120 kDa. It was initially described as a specific surface antigen of
human hematopoietic stem cells [4,5] and a marker for murine
neuroepithelial cells and several other embryonic epithelial cells
[6]. Although the biological functions of CD133 remain unknown
[7], CD133 alone or in combination with other markers is
currently used to isolate stem cells from numerous tissues [4,5], as
well as the prostate [8], liver [9] and pancreas [10,11]. Recently,
CD133 was reported to be a CSC marker in colon cancer [3,12].
Ieta et al. [13] further reported that CD133
+ cells derived from
colon cancer cell lines exhibit higher tumorigenic potential than
CD133
2 cells. However, Shmelkov et al. [14] demonstrated that
CD133 is widely expressed by human primary colon cancer
epithelial cells, and that both CD133
+ and CD133
2 metastatic
tumor subpopulations are capable of long-term tumorigenesis in
vivo. Therefore, the implications of CD133 as a CSC marker
remain controversial.
It has been suggested that the interactions between cancer cells
and the surrounding stromal fibroblasts have critical roles in tumor
invasion and metastasis [15,16]. Although bulk tumors are known
to consist of heterogeneous cancer cells with different proliferation,
invasion and metastasis activities, there are no reports focusing on
the heterogeneity of cancer-associated fibroblasts. In most previous
studies [17,18,19,20], only two or three primary cultures of
cancer-associated fibroblasts have been used for investigations.
Therefore, for a better understanding of cancer cell-stromal cell
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cancer-associated fibroblasts, similar to the heterogeneity of cancer
cells, such as CSCs.
In the present study, we investigated the biological implications
of CD133
+ colon cancer cells by analyzing CD133 expression in
human primary colon cancer tissues and evaluating the biological
behaviors of CD133
+ and CD133
2 cells derived from colon
cancer cell lines in vitro and in vivo. We found significant differences
in invasiveness between these two populations in cocultures with
primary fibroblasts derived from colon cancer tissues, especially in
cocultures with fibroblasts positive for CD10, a membrane
metalloendopeptidase. Taken together, these data suggest that
CD133
+ colon cancer cells are more invasive in the presence of
specific cancer-associated fibroblasts, especially CD10
+ fibroblasts,
and that these cell populations may be promising targets for
inhibiting metastasis and tumor recurrence.
Results
CD133 expression in surgically resected primary colon
cancer tissues
To date, inconsistent data have been reported regarding the
CD133
+ and CD133
2 cell populations in primary colon cancer
tissues [3,14]. We investigated the percentages of the CD133
+ and
CD133
2 cell populations in primary colon cancer tissues by flow
cytometry. We used 26 primary colon cancer tissues and 24
normal colon epithelial tissues from 26 patients. We analyzed the
CD133
+ populations in these colon tissues after excluding CD45
+
and CD31
+ cells. All the colon cancer samples contained both
CD133
+ and CD133
2 cells (Table 1; CD133
+ cells: 2–54%). We
also detected CD133
+ cells at 0–5% in normal colon tissues. To
evaluate the clinical implications of CD133 expression, we
investigated the correlations between CD133 expression and the
clinicopathological findings, such as tumor grade, Dukes classifi-
cation, lymph node metastasis, lymphatic invasion and venous
invasion (Table 2). We found significant correlations between
CD133 expression and Dukes classification (P=0.010) and
between CD133 expression and lymph node metastasis
(P=0.023).
Comparisons of malignant behaviors between sorted
CD133
+ and CD133
2 colon cancer cells
Using flow cytometry, we examined the presence of CD133
+
populations in 6 colon cancer cell lines. We found that all the cell
lines possessed CD133
+ cells (6–91%; Figure 1A). In particular, we
detected two distinct populations, one consisting of only CD133
+
Table 1. CD133, CD10 and other cell surface marker in colon cancer and normal tissues.
Case Age/ /Sex Site Grade Dukes CD133 CD24 CXCR4 C-Kit CD44 CD10 CD105 CD54
T/N T/N T/N T/N T/N T/N T/N T/N
1 58/M Sigmoid G2 C 2/- -/- -/- -/- -/- -/- -/- -/-
2 72/M Sigmoid G1 B 10/- -/- -/- -/- 14/- -/- -/- -/-
3 64/F Right G1 B 14/- -/- -/- -/- 91/34 -/- -/- -/-
4 63/F Right G2 C 25/2 -/- -/- -/- 22/14 2/3 -/- -/-
5 59/F Right G2 C 54/5 -/- -/- -/- 10/14 10/8 27/7 -/-
6 56/M Right G2 B 6/5 -/- -/- -/- 16/36 -/- -/- -/-
7 58/F Right G1 C 4/0 -/- -/- -/- 12/8 -/- -/- -/-
8 72/M Sigmoid G1 B 20/1 -/- 4/15 -/- 7/21 -/- -/- -/-
9 64/M Left G1 B 11/0 -/- 7/9 -/- 7/2 -/- -/- -/-
10 60/F Sigmoid G2 C 2/0 -/- -/- -/- 14/4 3/- 2/- -/-
11 53/M Right G1 C 21/0 -/- -/- 6/2 4/3 6/2 4/3 -/-
12 88/F Sigmoid G2 B 5/1 -/- -/- -/2 7/2 10/4 4/3 -/-
13 59/M Left G1 C 27/3 -/- -/- -/- 6/7 7/4 9/7 -/-
14 61/M Left G1 B 2/0 4/2 2/2 0.4/0.5 5/3 0.4/0.2 1/0.5 1.5/1
15 63/F Right G2 C 24/1 78/6 72/5 8/1 23/3 25/1 7/1 22/3
16 66/M Sigmoid G1 B 13/1 39/8 16/9 2/2 4/1 7/1 3/1 9/1
17 83/M Right G1 B 27/0 41/4 27/6 7/1 6/3 3/1 4/0.4 7/4
18 59/M Right G2 B 17/3 13/26 15/35 6/19 60/37 17/6 19/10 26/8
19 68/M Left G1 B 17/2 22/27 18/25 5/11 69/47 1/5 18/7 4/5
20 80/F Right G1 B 10/1 13/5 16/14 1/3 57/12 3/1 1.9/2 64/1
21 78/F Right G1 B 5/1 16/8 12/13 2/1.8 15/7 4/3 1.3/1 10/8
22 39/F Sigmoid G1 C 21/3 30/14 23/21 2/3 17/12 16/1 4/2 24/4
23 75/M Left G2 B 29/0 43/3 17/4 8/2 27/5 12/1 8/2 24/3
24 65/F Right G2 C 5/0 20/4 13/4 2/2 12/5 6/2 1/1 12/3
25 72/F Sigmoid G2 B 12/5 47/3 12/5 2/1 26/18 2/2 3/1 12/4
26 75/F Sigmoid G2 B 5/2 6/4 5/3 3/3 13/7 3/5 19/10 9/3
*Flow cytometry analysis for 26 patients. In table numeral is percentage.
doi:10.1371/journal.pone.0012121.t001
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2 cells, in DLD-1
cells, while the other cell lines appeared to possess one population
consisting of both CD133
+ and CD133
2 cells. We sorted DLD-1
cells on the basis of CD133 expression and reanalyses showed
effective selection (CD133
+: 98%; CD133
2: 100%; Figure 1B).
Subsequently, we investigated the time-dependent changes
in CD133 expression on unsorted DLD-1 parental cells and
sorted CD133
+ and CD133
2 cells. As shown in Figure 1B, sorted
CD133
+ cells showed significant time-dependent changes in the
CD133
+ and CD133
2 populations during long-time culture, while
the percentages of the CD133
+ and CD133
2 populations did not
change in the parental cells and sorted CD133
2 cells. Next, to
compare the biological behaviors of sorted CD133
+ and CD133
2
cells, we used DLD-1 and HCT116 cells and investigated their cell
proliferation, colony formation ability and chemoresistance to 5-
fluorouracil (5-Fu) and doxorubicin (DOX). We found no
significant differences in these cell behaviors between CD133
+
and CD133
2 cells (Figures S1, S2, S3, S4).
To evaluate the tumorigenic potential and in vivo tumor growth of
CD133
+ and CD133
2 DLD-1 cells, we transplanted serial numbers
of CD133
+ and CD133
2 cells into severe combined immunodefi-
ciency (SCID) mice. Although there was a trend toward earlier
detection of tumor formation in mice injected with CD133
+ cells
compared with mice injected with CD133
2 cells, the differences
were not significant (Table 3). At 10 weeks after transplantation,
injection of more than 5610
6 CD133
+ or CD133
2 cells generated
visible tumors in all mice. However, when the tumor sizes were
compared, the CD133
+ cell-derived tumors were significantly larger
than the CD133
2 cell-derived tumors (P=0.007; Figure 1C).
Cancer-associated fibroblasts enhance the invasiveness
of CD133
+ cells more effectively than that of CD133
2
cells
To elucidate the factors causing the differences in the in vivo
tumor growth between CD133
+ and CD133
2 cells, we investi-
gated the effects of cocultures with cancer-associated fibroblasts on
the invasiveness of these cells. We found that there was no
difference in invasiveness between CD133
+ and CD133
2 cells
when the cells were cultured alone (Figure 2A). In contrast, when
the cells were cocultured with cancer-associated fibroblasts,
CD133
+ cells showed significantly greater invasiveness than
CD133
2 cells and the parental cells (P,0.001 for both;
Figure 2A). We examined the effects of 12 primary cultures of
fibroblasts on the invasiveness of CD133
+ cells, and found that the
effects of the cocultured cells on CD133
+ cell invasion varied from
0.88-fold to 1.76-fold (Table 4).
Correlations between the percentages of cell surface
marker-positive populations in cancer-associated
fibroblasts and their enhancement of cancer invasion
To characterize the primary cultures of cancer-associated
fibroblasts, we examined the expressions of the stromal cell-
associated surface markers CD10, CD105, CD44 and CD54 on 32
primary cultures of fibroblasts by flow cytometry (Table 4). We
then investigated the correlations between the enhancement of
CD133
+ cell invasiveness and the percentages of positive
populations for these surface markers. We found a significant
correlation between the enhancement of CD133
+ cell invasiveness
Table 2. Relation between CD133 or CD10 expression and clinicopathological characteristics in colon adenocarcinoma.
CD133 expression CD10 expression
Variable
High
(§21%, n=8)
Low
(,21%, n=18) High rate P value
High
(§3.4%, n=12)
Low
(,3.4%, n=7) High rate P value
Age (yr)
,66 6 9 0.400 0.225 8 2 0.800 0.105
§66 2 9 0.182 4 5 0.444
Gender
Male 4 9 0.308 1 5 3 0.625 0.926
Female 4 9 0.308 7 4 0.636
Grade
G1 4 10 0.286 0.793 5 4 0.556 0.514
G2 4 8 0.333 7 3 0.700
Dukes
B 2 14 0.125 0.010* 5 6 0.455 0.051
C 6 4 0.600 7 1 0.875
Lymph
node Negative 2 13 0.133 0.023* 5 6 0.455 0.051
metastasis Positive 6 5 0.545 7 1 0.875
Lymphatic
invasion 0 4 13 0.235 0.277 7 5 0.636 0.565
1, 2 4 5 0.444 5 2 0.714
Venous
invasion 0 4 12 0.267 0.423 10 3 0.833 0.068
1, 2, 3 4 6 0.400 2 4 0.333
doi:10.1371/journal.pone.0012121.t002
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+ population (P,0.0001;
r=0.928; Figure 2B; Table 5). As shown in Table 4, the
percentage of the CD10
+ population in primary cultures of cancer-
associated fibroblasts established from colon tumors ranged from
0.39% to 73.33%. We also found a significant inverse correlation
between the percentages of the CD10
+ and CD105
+ populations
(P,0.0001; Table 5), as well as a significant inverse correlation
between the enhancement of CD133
+ cell invasiveness and the
percentage of the CD105
+ population (P=0.0268; Table 5).
Next, we investigated CD10 expression in surgically resected
primary tissues and found that 0.4–25% of the cells derived from
colon cancer tissues were CD10
+ (Table 1). We then examined the
correlations between the percentage of the CD10
+ population and
the clinicopathological findings. We found trends toward positive
correlations between the percentage of the CD10
+ population and
Dukes classification and between the percentage of the CD10
+
population and lymph node metastasis, although they were not
statistically significant (Table 2). We also investigated the
correlations among the cell surface markers in the same patients
and found a significant correlation between the percentages of the
CD133
+ and CD10
+ populations (P=0.015; r=0.4063;
Figure 2C).
CD10
+ fibroblasts enhance the in vitro invasion and
in vivo tumor growth of CD133
+ cancer cells
To investigate the functional differences between CD10
+ and
CD10
2 fibroblasts, we sorted CD10
+ and CD10
2 fibroblasts
(Figure 3A) from primary cultures of cancer-associated fibroblasts.
The levels of CD10 mRNA in these two populations were consistent
with the levels of CD10 cell surface protein expression (Figure 3A).
Using these two populations of fibroblasts, we investigated their
effects on the invasiveness of CD133
+ and CD133
2 cancer cells.
CD10
+ fibroblasts enhanced the invasiveness of CD133
+ cancer cells
significantly more than CD10
2 fibroblasts (P,0.0001; HCT116
cells, Figure 3B; DLD-1 cells, Figure 3C). CD10
+ fibroblasts also
slightlyenhancedtheinvasivenessofCD133
2cancercellsmorethan
CD10
2 fibroblasts, but significantly less than their effect on the
invasiveness of CD133
+ cancer cells (P,0.001; Figure 3C). To
evaluate the effectsofCD10
+and CD10
2fibroblastsoninvivotumor
growth, we cotransplanted CD133
+ or CD133
2 HCT116 cancer
cells and CD10
+ or CD10
2 fibroblasts into SCID mice. CD10
+
fibroblasts enhanced the tumor growth of CD133
+ cancer cells
significantly more than CD10
2 fibroblasts (P,0.05; Figure 3D).
Effect of CD10 knockdown in CD10
+ fibroblasts on the
invasion of cocultured colon cancer cells
To examine whether CD10 protein in fibroblasts functionally
contributes to the enhancement of invasion of cocultured cancer
cells, fibroblasts transfected with CD10-targeting small interfering
RNAs (siRNAs) (siRNA-1 and siRNA-2) or a control siRNA were
used for invasion assays. Both of the CD10-targeting siRNAs
inhibited 90% of CD10 mRNA expression. Knockdown of CD10
expressioninCD10
+fibroblastsremarkablyreducedtheinvasiveness
ofcocultured CD133
+ HCT116 cancer cells (P,0.001; Figure 4) but
had a limited effect on the invasiveness of CD133
2 cancer cells.
Differential expression profiling of CD10
+ and CD10
2
fibroblasts
To elucidate the key molecules involved in the CD10
+
fibroblast-mediated enhancement of the in vitro invasion and in
vivo tumor growth of CD133
+ colon cancer cells, we performed
microarray analyses using CD10
+ and CD10
2 primary-cultured
fibroblasts derived from colon tumors. Comparisons of the
microarray data between CD10
+ and CD10
2 primary-cultured
fibroblasts identified 20 genes that were upregulated by .2-fold in
CD10
+ fibroblasts (Table S1). To validate these microarray data,
qRT-PCR was performed. We selected ALDH1A1, GPNMB,
Figure 1. Biological behaviors of CD133
+ colon cancer cells in vitro and in vivo. (A) CD133
+ populations in a panel of human colon cancer
cell lines. Flow cytometry analyses were performed to investigate the CD133
+ populations in 6 colon cancer cell lines. (B) Analysis of the CD133
+
population in parental DLD-1 cells and reanalyses of sorted CD133
+ cells (98%) and CD133
2 cells (100%) (upper panels). The time-dependent changes
in the CD133
+ populations in unsorted parental and sorted CD133
+ and CD133
2 DLD-1 cells are also shown (lower panel). The sorted CD133
+ cells
show significant time-dependent changes in the CD133
+ and CD133
2 populations during long-time culture, while the percentages of the CD133
+
and CD133
2 populations do not change in the parental cells and sorted CD133
2 cells. (C) Tumor growth was evaluated at 1 month after injection of
5610
6 CD133
+ or CD133
2 DLD-1 cells into 6 SCID mice, respectively. Representative photographs are shown in the upper panel (left: CD133
2 cell-
derived tumor; right: CD133
+ cell-derived tumor). Scale bar=1 cm. The CD133
+ cell-derived tumors are significantly larger than the CD133
2 cell-
derived tumors (P=0.007; lower panel). Data represent means 6 SD.
doi:10.1371/journal.pone.0012121.g001
Table 3. Tumorigenic potential of CD133
+/CD133
2 cells derived from DLD-1 cells.
No. of mice with tumor formation
(Tumor volume .3cm
3)
No. of injected cells 6 Weeks 8 Weeks 10 Weeks
CD133
+ 4610
4 1/4 1/4 1/4
2610
5 1/5 1/5 1/5
1610
6 3/5 5/5
5610
6 4/4
CD133
2 4610
4 0/4 0/4 1/4
2610
5 0/5 0/5 1/5
1610
6 3/5 4/5 5/5
5610
6 4/4
doi:10.1371/journal.pone.0012121.t003
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these genes have been reported to be involved in cancer cell
invasion and colonic stem cells was also reported to express
ALDH1 [21,22,23,24,25]. The validated data were consistent with
the microarray data (Figure S5).
To evaluate the effects of CD10 knockdown on the expressions of
the four invasion-associated genes (MMP3, ALDH1A1, GPNMB and
IGFBP2) in CD10
+ fibroblasts, CD10
+ fibroblasts were transfected
with CD10-targeting or control siRNAs, and the expressions of
the four invasion-associated genes were assessed. There were no
significant changes in the expressionsof these four genes(Figure S6).
Discussion
In the present study, our in vitro experiments revealed that
CD10
+ fibroblasts derived from colon cancer tissues significantly
enhanced the invasion of CD133
+ colon cancer cells compared
with CD10
2 fibroblasts. We also found that knockdown of CD10
in CD10
+ fibroblasts partially reduced the invasiveness of
cocultured CD133
+ colon cancer cells. Furthermore, our in vivo
analyses demonstrated that cotransplantation of CD10
+ fibroblasts
significantly increased the tumor growth of CD133
+ colon cancer
cells compared with cotransplantation of CD10
2 fibroblasts.
Taken together, these data suggest that a specific subset of colon
cancer cells, CD133
+ cells, has important interactions with a
specific subset of cancer-associated fibroblasts, CD10
+ fibroblasts.
This is the first report to describe cancer cell-stromal cell
interactions between prospectively sorted specific subsets of colon
cancer cells and cancer-associated fibroblasts.
CSCs have been isolated from colon cancer on the basis of their
expression of the cell surface marker CD133 [3,12,26]. Although
several investigators have recently published reports about
CD133
+ colon cancer cells [3,12,26], there were inconsistent data
regarding the tumor-initiating ability of CD133
+ colon cancer
Figure 2. Cancer-associated fibroblasts enhance the malignant behaviors of CD133
+ colon cancer cells and the percentage of the
CD10
+ population in fibroblasts is correlated with colon cancer invasion. (A) Invading cells were measured after 48 h of monoculture or
coculture with cancer-associated fibroblasts (f11). CD133
+ cells cocultured with cancer-associated fibroblasts show significantly greater invasiveness
than CD133
2 cells and parental cells (P,0.001). Scale bars=100 mm. (B) The percentages of the CD10
+ cell population and the activities of these cells
to induce the invasion of cocultured colon cancer cells were investigated in 12 primary cultures of fibroblasts. There is a significant positive
correlation between the enhancement of CD133
+ cell invasiveness and the percentage of the CD10
+ cell population (P,0.0001). (C) Flow cytometry
analyses were performed to investigate the CD10
+ populations in primary colon cancer tissues. There is a significant correlation between the
percentages of the CD133
+ and CD10
+ populations in colon cancer tissues (P=0.015).
doi:10.1371/journal.pone.0012121.g002
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CD133
+ and CD133
2 colon cancer cells, consistent with the
results of Shmelkow et al. [14]. Furthermore, we found no
significant differences between these two cell populations in their in
vitro cell proliferation, colony formation and chemoresistance.
However, the present in vivo analyses revealed that CD133
+ cells
generated significantly larger tumors than CD133
2 cells. To
understand the implications of the inconsistent results between the
in vitro and in vivo experiments, we focused on cancer cell-stromal
cell interactions, which are known to have crucial roles in cancer
progression [27]. In cocultures with several primary cultures of
cancer-associated fibroblasts, the invasiveness of CD133
+ colon
cancer cells was significantly increased compared with that of
CD133
2 cells, while primary cultures of other cancer-associated
fibroblasts did not seem to have such potential to enhance the
invasiveness of cancer cells. Therefore, we characterized these
primary cultures of cancer-associated fibroblasts, and found that
CD10
+ fibroblasts played a significant role in the enhancement of
CD133
+ cancer cell invasiveness in in vitro and in vivo experiments.
In the present study, we used CD133
+ and CD133
2 cells
isolated from cultured cell lines because we were unable to obtain
reproducible results for tumorigenicity assays and coculture
experiments when we used CD133
+ and CD133
2 cells isolated
from patients’ tumors in a preliminary study. However, it is
important to investigate the biological behaviors of CD133
+ and
CD133
2 subpopulations isolated from patients’ tumors. There-
fore, further examinations are required to clarify the relationship
between primary tumor-derived CD133
+ cancer cells and CD10
+
fibroblasts. However, we need to improve our methods for
primary cultures of cancer cells before such examinations can be
performed. In addition, we used subcutaneous models in the
present study because of difficulties encountered in the assessment
of tumor size in orthotopic models. However, considering the
importance of the tissue microenvironment, studies using ortho-
topic models should be performed as the next step.
CD10 is a 90–100-kDa cell surface zinc-dependent metallopro-
tease that is widely expressed by the cells in various tissues, such as
lymphoid progenitor cells, myoepithelial cells and stromal cells of
the normal bone marrow and endometrium [28,29,30,31]. In
addition, CD10 was reported to be a marker for categorizing acute
leukemias and subclassifying malignant lymphomas [32]. Recent
immunohistochemical studies revealed that the frequency of
positive CD10 stromal expression in tumors was significantly
correlated with the prognosis of patients with breast cancers [18] as
well as the invasion and metastasis of gastric cancers [19]. Ogawa et
al. [31] performed an immunohistochemical study of colorectal
cancer and reported that expression of CD10 in stromal cells was
more frequently detected in invasive tumors than in non-invasive
tumors. The findings of these previous immunohistochemical
studies are consistent with those of our present functional study.
The present results demonstrated that knockdown of CD10
expression in CD10
+ fibroblasts partially, but significantly, decreased
the invasive ability of cocultured CD133
+ colon cancer cells. Our
microarray data identified several genes that are involved in the
invasion of cancer cells, but knockdown of CD10 expression did not
affect the expressions of these genes. The data may suggest that
CD10
+ fibroblasts have both CD10-dependent and CD10-indepen-
dent mechanisms to promote the invasion of cocultured CD133
+
colon cancer cells, although further examinations are required to
elucidate the detailed mechanisms of these interactions.
In conclusion, the present functional analyses suggest that
interactions between CD133
+ colon cancer cells and cancer-associated
CD10
+ fibroblasts have important roles in colon cancer progression.
These interactions may be promising targets for colon cancer therapies.
Table 4. Expression profiling of CD10, CD105, CD44 and
CD54 in primary cultures of fibroblasts.
CD10 CD105 CD44 CD54 Invasion
(CD133
+/CD133
2)
f1 26.67 59.55 94.22 1.37
f2 12.54 41.25 96.90 18.83 1.19
f3 5.76 85.17 96.65 0.88
f4-1 3.40 96.08 99.08 1.02
f4-2 7.98 75.42 97.86 1.05
f4-3 3.00 86.77 99.15
f5 30.06 70.18 99.66 1.21
f6 30.06 70.18 99.22 5.11 1.46
f7 0.87 96.14 98.62
f9 8.23 96.13 99.47 6.97 1.12
f10 9.47 84.52 96.50
f11 53.71 59.04 98.78 26.50 1.76
f12 8.12 88.45 99.94 8.65
f13 8.98 87.03 93.81 7.17 1.33
f14 6.86 82.49 97.69
f15 73.33 1.32 96.64 7.15
f16 40.78 59.07 96.24 24.42 1.57
f17 5.89 86.41 99.96 82.34 1.18
f18 56.24 42.40 98.55
f19 5.37 88.78 99.91 86.23
f20 2.34 78.17 99.56 79.99
f21 0.44 95.76 99.70 85.54
f22 0.39 85.00 97.73 20.86
f23 0.53 66.90 98.39 13.33
f24 18.02 64.62 99.75 71.46
f25 2.50 82.32 99.77 82.03
f26 3.86 83.93 99.78 94.02
f27 37.35 49.40 99.89 71.31
f28 36.52 60.44 99.75 72.78
f29 13.88 63.39 98.21 63.15
f31 25.16 52.65 89.74 13.44
f32 6.34 90.40 99.28 72.77
doi:10.1371/journal.pone.0012121.t004
Table 5. Correlation by CD10, CD105, CD44 and invasion.
Correlation
Coefficient (r)
P value
(Prob.|r|)
CD10 & CD105 20.7191 ,.0001*
CD44 & CD10 20.3150 0.0844
CD44 & CD105 0.5000 0.0453*
Invasion & CD10 0.9282 ,.0001*
Invasion & CD105 20.6340 0.0268*
Invasion & CD44 20.2028 0.5273
doi:10.1371/journal.pone.0012121.t005
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+ fibroblasts enhance the in vitro invasion and in vivo tumor growth of CD133
+ cancer cells. (A) Analysis of primary
cultures of colon cancer-associated fibroblasts (left panel) and reanalyses of sorted CD10
+ cells (middle upper panel) and CD10
2 cells (middle lower
panel). The CD10 mRNA levels in the sorted CD10
+ and CD10
2 fibroblasts were measured by qRT-PCR (right panel). (B, C) The invasiveness of CD133
+
and CD133
2 cancer cells cocultured with CD10
+ or CD10
2 fibroblasts was evaluated. Representative photographs are shown (B, HCT116 cells; C, DLD-
1 cells). Scale bars=100 mm. CD10
+ fibroblasts enhance the invasiveness of CD133
+ cancer cells significantly more than CD10
2 fibroblasts (P,0.0001).
(D) The effects of CD10
+ and CD10
2 fibroblasts on in vivo tumor growth were evaluated at 4 weeks after cotransplantation of CD133
+ or CD133
2
HCT116 cancer cells and CD10
+ or CD10
2 fibroblasts into SCID mice (n=6 for each group). Representative photographs are shown (upper panel).
Scale bar=1 cm. CD10
+ fibroblasts enhance the tumor growth of CD133
+ HCT116 cancer cells significantly more than CD10
2 fibroblasts (P,0.05;
lower panel). Data represent means 6 SD.
doi:10.1371/journal.pone.0012121.g003
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Ethics statement
The study was approved by the Ethics Committee of Kyushu
University (approval number, 19-13) and conducted according to
the Ethical Guidelines for Human Genome/Gene Research
enacted by the Japanese Government. All the patients provided
signed informed consent approving the use of their tissues for
unspecified research purposes. For all experiments involving mice,
the animals were housed in laminar-flow cabinets under specific
pathogen-free conditions in facilities approved by Kyushu
University (approval number, A020-018-0).
Cells and reagents
Human colon cancer cell lines (DLD-1, RCM1 and Colo201)
were purchased from the Japanese Collection of Research
Bioresources (Osaka, Japan). The LOVO and Colo205 cell lines
were obtained from RIKEN (Tsukuba, Japan) and the HCT116
cell line was obtained from the American Type Culture Collection
(Manassas, VA). We established 32 primary cultures of colon
cancer-associated fibroblasts derived from resected colon tumors
from 26 patients as described previously [33]. The cells were
cultured in DMEM supplemented with streptomycin (100 mg/ml),
penicillin (100 U/ml) and 10% fetal bovine serum (FBS) at 37uC
in a humidified environment of 90% air and 10% CO2. All the
experiments were performed using cells cultured in medium
supplemented with 10% FBS. All the tissue samples were obtained
at the time of surgery at the Department of Surgery I, Kyushu
University Hospital (Fukuoka, Japan). Experienced pathologists
performed histologic examinations of all tissues adjacent to the
specimens.
5-Fu and DOX were kindly provided by Wako Pure Chemical
Industries (Osaka, Japan) and Nippon Roche K.K. (Kamakura,
Japan), respectively.
Flow cytometry
The tissue samples were washed extensively with phosphate-
buffered saline (PBS), minced into approximately 1-mm
3 cubes
using scissors and dissociated into single cells by digestion with
collagenase (Wako Pure Chemical Industries). The dissociated cells
were passed through a filter. Primary cells derived from the
resected tissues and dissociated DLD-1 cells were suspended in ice-
cold 1% FBS in PBS at 1610
6 cells/100 ml. Each suspension was
incubated with an antibody on ice for 40 min. The labeled cells
were analyzed using an EPICS ALTRA flow cytometer (Beckman
Coulter Inc., Fullerton, CA) equipped with two lasers that
provided excitation wavelengths of 488 nm for the fluorescein
isothiocyanate (FITC), phycoerythrin (PE) and propidium iodide
(PI) signals and 635 nm for the allophycocyanin (APC) signals.
The resulting fluorescence emissions were collected using band
pass filter sets at 525615 nm for FITC, 575610 nm for PE,
610612 nm for PI and 675625 nm for APC. EXPO32 flow
cytometry software (Beckman Coulter Inc.) was used to quantify
the fluorescence signals and to set the logical electronic-gating
parameters. The primary antibodies used for the FACS analyses
are listed in Table S2.
qRT-PCR
Total RNA was extracted from cultured and/or sorted cells
using a High Pure RNA Isolation Kit (Roche Diagnostics,
Mannheim, Germany) with DNase I (Roche Diagnostics)
treatment, according to the manufacturer’s instructions. We
designed specific primers (Table S3) and performed BLAST
searches to ensure the specificities of these primers. One-step qRT-
PCR was performed using a QuantiTect SYBR Green Reverse
Transcription-PCR Kit (Qiagen K.K., Tokyo, Japan) and a
Chromo4 Real-Time PCR Detection System (Bio-Rad Laborato-
ries, Hercules, CA), as described previously [34]. Each sample was
run in triplicate and the expression of each gene was presented as
Figure 4. Invasiveness of CD133
+ and CD133
2 HCT116 cells
cocultured with fibroblasts transfected with control or CD10-
targeting siRNAs. Knockdown of CD10 expression in CD10
+ fibroblasts
remarkably reduces the invasiveness of cocultured CD133
+ HCT116
cancer cells (P,0.001), but has a limited effect on the invasiveness of
CD133
2 cancer cells. Representative photographs (upper panels) and
graphs (lower panel) are shown. Scale bars=100 mm.
doi:10.1371/journal.pone.0012121.g004
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that of 18S rRNA.
CD10 siRNAs
Inhibition of CD10 gene expression was achieved by RNA
interference with siRNAs against CD10 (siRNA-1: sense, 59-
GGUUGAAUUUCACAAAUGATT-39, antisense, 59-UCAUU-
UGUGAAAUUCAACCAG-39; siRNA-2: sense, 59-GUGUGG-
UGUGGAACCUAUATT-39, antisense, 59-UAUAGGUUCCA-
CACCACACCT-39; Qiagen, Poison Information Center Mainz,
Germany) as described previously [35]. To verify the specificity
of the knockdown effects, we used a control siRNA (Qiagen).
Fibroblasts were transfected with 100 pmol of the appropriate
siRNA using Nucleofector (Amaxa Biosystems, Ko ¨ln, Germany)
according to the manufacturer’s instructions.
In vitro invasion assay
The invasiveness of colon cancer cells was assessed based on the
number of cells invading through Matrigel-coated transwell
chambers (BD, Franklin Lakes, NJ) as described previously [36].
Briefly, transwell inserts with 8-mm pores were coated with
Matrigel (20 mg/well; BD, Bedford, MA). Cells (5610
4 cells/ml)
were seeded in the upper chambers. For cocultures, 5610
4
fibroblasts were seeded in the lower chambers. Thereafter, the
cells were incubated for 48 h. Cells that invaded to the lower
surface of the Matrigel-coated membrane were counted in five
random fields at 2006 magnification under a light microscope
(ECLIPSE TE2000; Nikon, Tokyo, Japan). The results were
expressed as the mean number of invading cells. Each experiment
was carried out in triplicate wells, and independent experiments
were repeated more than three times.
Cell proliferation assay
Cell proliferation was evaluated by measuring the fluorescence
intensity of PI, as described previously [36]. All experiments were
performed in triplicate wells and repeated more than three times.
In vivo experiments
Sorted DLD-1 or HCT116 colon cancer cells and cancer-
associated fibroblasts were suspended in 100 ml of DMEM
supplemented with 10% FBS, and subcutaneously transplanted
into the limbs of 18 5-week-old female NOD/SCID mice
(NOD.CB17-Prkdc
scid/shiJic; Kyudo Co. Ltd., Tosu, Japan)
[37]. Tumor appearance was evaluated using a caliper, and tumor
volume was calculated using the formula p/66(L6W6W), where
L represents the largest tumor diameter and W represents the
smallest tumor diameter. After different times of tumor growth,
the animals were sacrificed.
Microarray analysis
We performed microarray analyses using CD10
+ and CD10
2
primary colon fibroblasts. The qualities of the RNA samples were
evaluated using a 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, Germany) as previously described [38]. We used a
HumanWG-6 Expression BeadChip (Illumina, San Diego, CA) for
these analyses. The data were analyzed using BeadStudio software
version 3.2.3 (Illumina). All of the microarray data were deposited
in CIBEX under the accession number CBX125 (http://cibex.
nig.ac.jp/index.jsp).
Statistical analyses
Statistical analyses were performed using JMP version 7.0.1
software (SAS Institute, Cary, NC). The CD133 and CD10
expressions were split into high- and low-level groups using recursive
descent partition analysis, as described by Hoffmann et al. [39]. All
data were expressed as the mean 6 SD. The significance of
differences between groups was estimated by Student’s t-test and/or
Spearman rank correlation analysis and repeated-measures AN-
OVA. Differences were considered significant at P,0.05.
Supporting Information
Figure S1 Proliferation assay for unsorted DLD-1 (left panel)
and HCT116 (right panel) parental cells and sorted CD133+ and
CD1332 colon cancer cells. Cells (26104) were seeded and
evaluated at 2 and 4 days after seeding by PI assays. Data
represent means 6 SD.
Found at: doi:10.1371/journal.pone.0012121.s001 (0.42 MB TIF)
Figure S2 Colony formation assays for CD133+ and CD1332
DLD-1 cells. Cells were propagated to allow colony formation for
14 days. Data represent means 6 SD.
Found at: doi:10.1371/journal.pone.0012121.s002 (0.20 MB TIF)
Figure S3 Resistance of CD133+ and CD1332 DLD-1 cells to
the anticancer agents 5-Fu (left panel) and DOX (right panel).
Cells (36104) were seeded and evaluated after 72 h of 5-Fu or
DOX treatment. Data represent the fold changes in the number of
viable cells (day 3/day 0).
Found at: doi:10.1371/journal.pone.0012121.s003 (0.39 MB TIF)
Figure S4 Resistance of CD133+ and CD1332 HCT116 cells
to the anticancer agents 5-Fu (left panel) and DOX (right panel).
Cells (36104) were seeded and evaluated after 72 h of 5-Fu or
DOX treatment. Data represent the fold changes in the number of
viable cells (day 3/day 0).
Found at: doi:10.1371/journal.pone.0012121.s004 (0.38 MB TIF)
Figure S5 Differential expression profiling of CD10+ and
CD102 fibroblasts (f1). The validated data obtained by qRT-
PCR are consistent with the microarray data. P,0.05 for all data.
Found at: doi:10.1371/journal.pone.0012121.s005 (0.25 MB TIF)
Figure S6 Expression profiling of the CD10 cell population.
Upper panel, CD10 expression in f2 fibroblasts transfected with
control or CD10-targeting siRNAs. Lower panel, Effect of
inhibition of CD10 on the expressions of CD10, MMP3,
ALDH1A1, GPNMB and IGFBP2 in CD10+ fibroblasts. Black
bars: control siRNA; gray bars: CD10 siRNA-1; white bars: CD10
siRNA-2. The expressions of CD10, MMP3, ALDH1A1,
GPNMB and IGFBP2 was normalized by the expression of 18S
rRNA. Data represent means 6 SD.
Found at: doi:10.1371/journal.pone.0012121.s006 (0.53 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0012121.s007 (0.04 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0012121.s008 (0.03 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0012121.s009 (0.03 MB
DOC)
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